Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

NCT04088110 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Female
HER2-positive Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast
Metastatic Breast Cancer
Breast Diseases
Hormone Receptor Positive Tumor

Interventions

DRUG: Pyrotinib
DRUG: Trastuzumab
DRUG: Aromatase Inhibitors

Sponsor

Fuzhou General Hospital